Home > Journals > Italian Journal of Dermatology and Venereology > Past Issues > Italian Journal of Dermatology and Venereology 2024 June;159(3) > Italian Journal of Dermatology and Venereology 2024 June;159(3):251-78

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

GUIDELINES   Open accessopen access

Italian Journal of Dermatology and Venereology 2024 June;159(3):251-78

DOI: 10.23736/S2784-8671.24.07666-7

Copyright © 2024 THE AUTHORS

This is an open access article distributed under the terms of the CC BY-NC 4.0 license which allows users to distribute, remix, adapt and build upon the manuscript, as long as this is not done for commercial purposes, the user gives appropriate credits to the original author(s) and the source (with a link to the formal publication through the relevant DOI), provides a link to the license and indicates if changes were made.

language: English

Italian S3-Guideline on the treatment of Atopic Eczema - Part 2: non-systemic treatments and treatment recommendations for special AE patient populations, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA)

Authors of the Italian Adaption of the EuroGuiDerm Guidelines: Giuseppe ARGENZIANO 1, Francesco CUSANO 2, Monica CORAZZA 3, Salvatore AMATO 4, Paolo AMERIO 5, Luigi NALDI 6, Cataldo PATRUNO 7, Paolo D. PIGATTO 8, Pietro QUAGLINO 9, Paolo GISONDI 10, Andrea CHIRICOZZI 11, 12, Francesco TONON 13, Luca STINGENI 14, Piergiacomo CALZAVARA-PINTON 13
Original authors: Andreas WOLLENBERG 15, 16, Maria KINBERGER 17, Bernd W. ARENTS 18, Nora ASZODI 15, Gabriela L. AVILA VALLE 17, Sebastien BARBAROT 19, Thomas BIEBER 20, Helen A. BROUGH 21, 22, Piergiacomo CALZAVARA-PINTON 13, Stéphanie CHRISTEN-ZÄCH 23, Mette DELEURAN 24, Martin DITTMANN 17, Corinna DRESSLER 17, Antjie H. FINK-WAGNER 25, Nicole FOSSE 26, Krisztián GÁSPÁR 27, Louise A. GERBENS 28, Uwe GIELER 29, Giampiero GIROLOMONI 30, Stamatios GREGORIOU 31, Charlotte G. MORTZ 32, Alexander NAST 17, Uffe NYGAARD 33, Magali REDDING 34, Eva M. REHBINDER 35, Johannes RING 36, Mariateresa ROSSI 37, Esther SERRA-BALDRICH 38, Dagmar SIMON 39, Zsuzsanna Z. SZALA I 40, Jacek C. SZEPIETOWSKI 41, Antonio TORRELO 42, Thomas WERFEL 43, Carsten FLOHR 44, 45

1 Dermatology Unit, University of Campania Luigi Vanvitelli, Naples, Italy; 2 Dermatology Unit, G. Rummo Hospital, Benevento, Italy; 3 Section of Dermatology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy; 4 Department of Dermatology and Sexually Transmitted Diseases, ARNAS-Palermo, Palermo, Italy; 5 Section of Dermatology, Department of Medicine and Aging Science, G. D’Annunzio University, Chieti, Italy; 6 Dermatology Unit, San Bortolo Hospital, Vicenza, Italy; 7 Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy; 8 Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy; 9 University of Turin Medical School, Department of Medical Sciences, Dermatologic Clinic, Turin, Italy; 10 Dermatology and Venereology Section, Department of Medicine, University of Verona, Verona, Italy; 11 Unit of Dermatology, Department of Medical and Surgical Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy; 12 Unit of Dermatology, Department of Translational Medicine and Surgery, Sacred Heart Catholic University, Rome, Italy; 13 Department of Dermatology, University of Brescia, Brescia, Italy; 14 Section of Dermatology, Department of Medicine, University of Perugia, Perugia, Italy; 15 Department of Dermatology and Allergy, Ludwig Maximilian University, Munich, Germany; 16 Department of Dermatology, Free University of Brussel (VUB), Brussels University Hospital (UZ Brussel), Brussels, Belgium; 17 Division of Evidence-Based Medicine(dEBM), Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany; 18 European Federation of Allergy and Airways Diseases Patients’ Associations (EFAefa), Brussels, Belgium; 19 Department of Dermatology, CHU Nantes, UMR 1280 PhAN, INRAE , Nantes University, Nantes, France; 20 Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany; 21 Children’s Allergy Service, Evelina London Children’s Hospital, Guy’s and St. Thomas’ NHS Foundation Trust, London, UK; 22 Paediatric Allergy Group, Department of Women and Children’s Health, School of Life Course Sciences, King’s College London, London, UK; 23 University Hospital Lausanne, Lausanne, Switzerland; 24 Aarhus University Hospital, Aarhus, Denmark; 25 Global Allergy and Airways Diseases Patient Platform (GAAPP), Vienna, Austria; 26 Department of Dermatology, University Hospital Basel, Basel, Switzerland; 27 Department of Dermatology of the University of Debrecen, Debrecen, Hungary; 28 Department of Dermatology, Amsterdam UMC (University Medical Centers), Amsterdam, the Netherlands; 29 Department of Dermatology, University of Giessen, Giessen, Germany; 30 Dermatology and Venereology Section, Department of Medicine, University of Verona, Verona, Italy; 31 Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece; 32 Department of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark, Odense, Denmark; 33 Department of Dermato-Venerology, Aarhus University Hospital, Aarhus, Denmark; 34 Eczema Outreach Support, Linlithgow, UK; 35 Dermatology Department, Oslo University Hospital, Oslo, Norway; 36 Department of Dermatology Allergology Biederstein, Technical University Munich, Munich, Germany; 37 Dermatology Unit, Spedali Civili Hospital Brescia, Brescia, Italy; 38 Dermatology, Hospital of Sant Pau, Barcelona, Spain; 39 Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; 40 Pediatric Dermatology Unit, Heim Pa’l National Children’s Institute Budapest, Budapest, Hungary; 41 Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland; 42 Hospital Infantil Niño Jesús, Madrid, Spain; 43 Hannover Medical School, Hannover, Germany; 44 St John’s Institute of Dermatology, King’s College London, London, UK; 45 Guy’s and St Thomas’ NHS Foundation Trust, London, UK


PDF


SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of the present guideline on the systemic treatment of chronic plaque psoriasis. With the permission of EuroGuiDerm, SIDeMaST adapted the guideline to the Italian healthcare context to supply a reliable and affordable tool to Italian physicians who take care of patients affected by atopic dermatitis. The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. Four consensus conferences were held between December 2020 and July 2021. Twenty-nine experts (including clinicians and patient representatives) from 12 European countries participated. This second part of the guideline includes recommendations and detailed information on basic therapy with emollients and moisturizers, topical anti-inflammatory treatment, antimicrobial and antipruritic treatment and UV phototherapy. Furthermore, this part of the guideline covers techniques for avoiding provocation factors, as well as dietary interventions, immunotherapy, complementary medicine and educational interventions for patients with atopic eczema and deals with occupational and psychodermatological aspects of the disease. It also contains guidance on treatment for pediatric and adolescent patients and pregnant or breastfeeding women, as well as considerations for patients who want to have a child. A chapter on the patient perspective is also provided. The first part of the guideline, published separately, contains recommendations and guidance on systemic treatment with conventional immunosuppressive drugs, biologics and janus kinase (JAK) inhibitors, as well as information on the scope and purpose of the guideline, and a section on guideline methodology.


KEY WORDS: Eczema; Guideline; Consensus

top of page